Vitamin D from Dietary Intake and Sunlight Exposure and the Risk of Hormone-Receptor-Defined Breast Cancer
Vitamin D from Dietary Intake and Sunlight Exposure and the Risk of Hormone-Receptor-Defined Breast Cancer
复制标题
DOI：
10.1093/aje/kwn198
复制
发表时间：
2008-10-15
影响因子：
5
通讯作者：
Knight, Julia A.
中科院分区：
文献类型：
--
作者：
Blackmore, Kristina M.;Lesosky, Maia;Knight, Julia A.
已有证据表明维生素 D 在乳腺癌发生过程中发挥作用，并且有证据表明维生素 D 在激素受体阳性细胞中的抗增殖作用更大。很少有流行病学研究考虑维生素 D 与激素受体定义的乳腺癌之间的关联，而且结果是相互矛盾的。作者考虑了一项病例对照研究（加拿大安大略省，2003-2005 年）中的 759 例病例和 1,135 例对照，研究了特定年龄的维生素 D 摄入量与雌激素受体 (ER) 和孕激素受体 (PR) 联合定义的乳腺癌之间的关联。虽然增加维生素 D 摄入量（来自阳光和饮食）与显着降低 ER+/PR+ 肿瘤风险最一致（例如，青春期使用鱼肝油的比值比 = 0.76，95% 置信区间：0.59、0.97），但发现受体阴性 (ER-/PR-) 存在类似的非显着关联（比值比 = 0.74，95% 置信区间： 0.53, 1.04) 和混合 (ER+/PR-)（比值比 = 0.79，95% 置信区间：0.51, 1.22）肿瘤。这项研究表明，无论肿瘤的 ER/PR 状态如何，维生素 D 都与降低乳腺癌风险相关。未来需要对大量受体阴性和混合肿瘤进行研究。
Evidence has emerged for a role of vitamin D in the development of breast cancer, and there is some suggestion that its antiproliferative effect is greater in hormone-receptor-positive cells. Few epidemiologic studies have considered the association between vitamin D and hormone-receptor-defined breast cancer, and the results are conflicting. Considering 759 cases and 1,135 controls from a case-control study (Ontario, Canada, 2003-2005), the authors examined the association between vitamin D intake at specific ages and combined estrogen-receptor- (ER) and progesterone-receptor- (PR) defined breast cancer. While increased intake of vitamin D (from the sun and diet) was most consistently associated with a significantly reduced risk of ER+/PR+ tumors (e.g., odds ratio = 0.76, 95% confidence interval: 0.59, 0.97 for use of cod liver oil during adolescence), comparable nonsignificant associations were found for receptor-negative (ER-/PR-) (odds ratio = 0.74, 95% confidence interval: 0.53, 1.04) and mixed (ER+/PR-) (odds ratio = 0.79, 95% confidence interval: 0.51, 1.22) tumors. This study suggests that vitamin D is associated with a reduced risk of breast cancer regardless of ER/PR status of the tumor. Future studies with a larger number of receptor-negative and mixed tumors are required.